Skip to main content
Top
Published in:

Open Access 09-05-2024 | Prostate Cancer | Original Article

Men with metastatic prostate cancer carrying a pathogenic germline variant in breast cancer genes: disclosure of genetic test results to relatives

Authors: Michiel Vlaming, Margreet G. E. M. Ausems, Gina Schijven, Inge M. van Oort, C. Marleen Kets, Fenne L. Komdeur, Lizet E. van der Kolk, Rogier A. Oldenburg, Rolf H. Sijmons, Lambertus A. L. M. Kiemeney, Eveline M. A. Bleiker

Published in: Familial Cancer | Issue 2/2024

Login to get access

Abstract

Some patients with metastatic prostate cancer carry a pathogenic germline variant (PV) in a gene, that is mainly associated with an increased risk of breast cancer in women. If they test positive for such a PV, prostate cancer patients are encouraged to disclose the genetic test result to relatives who are at risk in case the carrier status changes the relatives’ medical care. Our study aimed to investigate how men who learned they carry a PV in BRCA1, BRCA2, PALB2, CHEK2 or ATM disclosed their carrier status to at-risk relatives and to assess the possible psychological burden for the carrier and their perception of the burden for relatives. In total, 23 men with metastatic prostate cancer carrying a PV completed the IRI questionnaire about family communication; 14 also participated in a semi-structured interview. Patients felt highly confident in discussing the genetic test result with relatives. The diagnosis of prostate cancer was experienced as a burden, whereas being informed about genetic testing results did in most cases not add to this burden. Two patients encountered negative experiences with family communication, as they considered the genetic test result to be more urgent than their relatives. This mixed-methods study shows that metastatic prostate cancer patients with a PV in genes mainly associated with increased risk of breast cancer feel well-equipped to communicate about this predisposition in their families. Carriers felt motivated to disclose their genetic test result to relatives. Most of them indicated that the disclosure was not experienced as a psychological burden.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sung H et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249CrossRefPubMed Sung H et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249CrossRefPubMed
2.
go back to reference Buzzoni C et al (2015) Metastatic prostate cancer incidence and prostate-specific antigen testing: new insights from the European randomized study of screening for prostate cancer. Eur Urol 68(5):885–890PubMedPubMedCentralCrossRef Buzzoni C et al (2015) Metastatic prostate cancer incidence and prostate-specific antigen testing: new insights from the European randomized study of screening for prostate cancer. Eur Urol 68(5):885–890PubMedPubMedCentralCrossRef
3.
go back to reference Hamdy FC et al (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375(15):1415–1424PubMedCrossRef Hamdy FC et al (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375(15):1415–1424PubMedCrossRef
4.
go back to reference Abdi B et al (2022) DNA damage repair gene germline profiling for metastatic prostate cancer patients of different ancestries. Prostate 82(12):1196–1201PubMedCrossRef Abdi B et al (2022) DNA damage repair gene germline profiling for metastatic prostate cancer patients of different ancestries. Prostate 82(12):1196–1201PubMedCrossRef
5.
go back to reference Abida W et al (2017) Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol 1:1–16CrossRef Abida W et al (2017) Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol 1:1–16CrossRef
6.
go back to reference Boyle JL et al (2020) Pathogenic germline DNA repair gene and HOXB13 mutations in men with metastatic prostate cancer. JCO Precis Oncol 4:139–151CrossRef Boyle JL et al (2020) Pathogenic germline DNA repair gene and HOXB13 mutations in men with metastatic prostate cancer. JCO Precis Oncol 4:139–151CrossRef
7.
go back to reference Castro E et al (2019) PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. J Clin Oncol 37(6):490–503PubMedCrossRef Castro E et al (2019) PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. J Clin Oncol 37(6):490–503PubMedCrossRef
8.
go back to reference Giri VN et al (2017) Inherited mutations in men undergoing multigene panel testing for prostate cancer: emerging implications for personalized prostate cancer genetic evaluation. JCO Precis Oncol 1:1–17CrossRef Giri VN et al (2017) Inherited mutations in men undergoing multigene panel testing for prostate cancer: emerging implications for personalized prostate cancer genetic evaluation. JCO Precis Oncol 1:1–17CrossRef
9.
go back to reference Greenberg SE et al (2021) Clinical germline testing results of men with prostate cancer: patient-level factors and implications of NCCN guideline expansion. JCO Precis Oncol 5:533–542CrossRef Greenberg SE et al (2021) Clinical germline testing results of men with prostate cancer: patient-level factors and implications of NCCN guideline expansion. JCO Precis Oncol 5:533–542CrossRef
10.
go back to reference Hart SN et al (2016) Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer. BMJ Open 6(4):e010332PubMedPubMedCentralCrossRef Hart SN et al (2016) Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer. BMJ Open 6(4):e010332PubMedPubMedCentralCrossRef
11.
go back to reference Isaacsson Velho P et al (2018) Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer. Prostate 78(5):401–407PubMedCrossRef Isaacsson Velho P et al (2018) Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer. Prostate 78(5):401–407PubMedCrossRef
12.
go back to reference Na R et al (2017) Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death. Eur Urol 71(5):740–747PubMedCrossRef Na R et al (2017) Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death. Eur Urol 71(5):740–747PubMedCrossRef
13.
go back to reference Nguyen-Dumont T et al (2021) Rare germline pathogenic variants identified by multigene panel testing and the risk of aggressive prostate cancer. Cancers 13(7):1495PubMedPubMedCentralCrossRef Nguyen-Dumont T et al (2021) Rare germline pathogenic variants identified by multigene panel testing and the risk of aggressive prostate cancer. Cancers 13(7):1495PubMedPubMedCentralCrossRef
14.
go back to reference Nicolosi P et al (2019) Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines. JAMA Oncol 5(4):523–528PubMedPubMedCentralCrossRef Nicolosi P et al (2019) Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines. JAMA Oncol 5(4):523–528PubMedPubMedCentralCrossRef
15.
go back to reference Petrovics G et al (2019) Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population. Prostate Cancer Prostatic Dis 22(3):406–410PubMedCrossRef Petrovics G et al (2019) Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population. Prostate Cancer Prostatic Dis 22(3):406–410PubMedCrossRef
19.
go back to reference Yadav S et al (2019) Contribution of inherited DNA-repair gene mutations to hormone-sensitive and castrate-resistant metastatic prostate cancer and implications for clinical outcome. JCO Precis Oncol 3:1–12CrossRef Yadav S et al (2019) Contribution of inherited DNA-repair gene mutations to hormone-sensitive and castrate-resistant metastatic prostate cancer and implications for clinical outcome. JCO Precis Oncol 3:1–12CrossRef
20.
go back to reference Bychkovsky BL et al (2022) Differences in cancer phenotypes among frequent CHEK2 Variants and implications for clinical care—checking CHEK2. JAMA Oncol 8(11):1598–1606PubMedPubMedCentralCrossRef Bychkovsky BL et al (2022) Differences in cancer phenotypes among frequent CHEK2 Variants and implications for clinical care—checking CHEK2. JAMA Oncol 8(11):1598–1606PubMedPubMedCentralCrossRef
21.
go back to reference Hall MJ et al (2021) Germline pathogenic variants in the ataxia telangiectasia mutated (ATM) gene are associated with high and moderate risks for multiple cancers germline ATM PVs are associated with multiple cancer risks. Cancer Prev Res 14(4):433–440CrossRef Hall MJ et al (2021) Germline pathogenic variants in the ataxia telangiectasia mutated (ATM) gene are associated with high and moderate risks for multiple cancers germline ATM PVs are associated with multiple cancer risks. Cancer Prev Res 14(4):433–440CrossRef
23.
go back to reference Yang X et al (2020) Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families. J Clin Oncol 38(7):674PubMedCrossRef Yang X et al (2020) Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families. J Clin Oncol 38(7):674PubMedCrossRef
25.
go back to reference Carbine NE et al (2018) Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Rev 4(4):CD002748PubMed Carbine NE et al (2018) Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Rev 4(4):CD002748PubMed
26.
go back to reference Ludwig KK et al (2016) Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. The American Journal of Surgery 212(4):660–669PubMedCrossRef Ludwig KK et al (2016) Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. The American Journal of Surgery 212(4):660–669PubMedCrossRef
27.
go back to reference Wood ME, McKinnon W, Garber J (2020) Risk for breast cancer and management of unaffected individuals with non-BRCA hereditary breast cancer. Breast J 26(8):1528–1534PubMedCrossRef Wood ME, McKinnon W, Garber J (2020) Risk for breast cancer and management of unaffected individuals with non-BRCA hereditary breast cancer. Breast J 26(8):1528–1534PubMedCrossRef
28.
go back to reference Page EC et al (2019) Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers. Eur Urol 76(6):831–842PubMedPubMedCentralCrossRef Page EC et al (2019) Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers. Eur Urol 76(6):831–842PubMedPubMedCentralCrossRef
29.
go back to reference de Bono JS et al (2021) Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. Lancet Oncol 22(9):1250–1264PubMedCrossRef de Bono JS et al (2021) Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. Lancet Oncol 22(9):1250–1264PubMedCrossRef
31.
go back to reference Hussain M et al (2020) Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med 383(24):2345–2357PubMedCrossRef Hussain M et al (2020) Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med 383(24):2345–2357PubMedCrossRef
33.
go back to reference Dheensa S, Lucassen A, Fenwick A (2018) Limitations and pitfalls of using family letters to communicate genetic risk: a qualitative study with patients and healthcare professionals. J Genet Couns 27:689–701PubMedCrossRef Dheensa S, Lucassen A, Fenwick A (2018) Limitations and pitfalls of using family letters to communicate genetic risk: a qualitative study with patients and healthcare professionals. J Genet Couns 27:689–701PubMedCrossRef
34.
go back to reference Finn CM et al (2023) Motivation and family communication in hereditary prostate cancer genetic testing: survey of patients from a US tertiary medical center. J Genet Couns 32(1):79–89PubMedCrossRef Finn CM et al (2023) Motivation and family communication in hereditary prostate cancer genetic testing: survey of patients from a US tertiary medical center. J Genet Couns 32(1):79–89PubMedCrossRef
35.
go back to reference Leader AE et al (2022) Insight into how patients with prostate cancer interpret and communicate genetic test results: implications for families. J Community Genet 13(6):547–556PubMedPubMedCentralCrossRef Leader AE et al (2022) Insight into how patients with prostate cancer interpret and communicate genetic test results: implications for families. J Community Genet 13(6):547–556PubMedPubMedCentralCrossRef
36.
go back to reference Vlaming M et al (2022) Mainstream germline genetic testing in men with metastatic prostate cancer: design and protocol for a multicenter observational study. BMC Cancer 22(1):1365PubMedPubMedCentralCrossRef Vlaming M et al (2022) Mainstream germline genetic testing in men with metastatic prostate cancer: design and protocol for a multicenter observational study. BMC Cancer 22(1):1365PubMedPubMedCentralCrossRef
37.
go back to reference Kroll T, Neri M (2009) Designs for mixed methods research. Mixed methods research for nursing and the health sciences. Wiley, Hoboken, pp 31–49 Kroll T, Neri M (2009) Designs for mixed methods research. Mixed methods research for nursing and the health sciences. Wiley, Hoboken, pp 31–49
38.
go back to reference Kuper A, Lingard L, Levinson W (2008) Critically appraising qualitative research. BMJ 337:a1035–a1035PubMedCrossRef Kuper A, Lingard L, Levinson W (2008) Critically appraising qualitative research. BMJ 337:a1035–a1035PubMedCrossRef
40.
go back to reference de Geus E et al (2015) Development of the informing relatives inventory (IRI): assessing index patients’ knowledge, motivation and self-efficacy regarding the disclosure of hereditary cancer risk information to relatives. Int J Behav Med 22:551–560PubMedCrossRef de Geus E et al (2015) Development of the informing relatives inventory (IRI): assessing index patients’ knowledge, motivation and self-efficacy regarding the disclosure of hereditary cancer risk information to relatives. Int J Behav Med 22:551–560PubMedCrossRef
41.
go back to reference Claes E et al (2003) Communication with close and distant relatives in the context of genetic testing for hereditary breast and ovarian cancer in cancer patients. Am J Med Genet A 116(1):11–19CrossRef Claes E et al (2003) Communication with close and distant relatives in the context of genetic testing for hereditary breast and ovarian cancer in cancer patients. Am J Med Genet A 116(1):11–19CrossRef
42.
go back to reference Braun V, Clarke V (2006) Using thematic analysis in psychology. Qual Res Psychol 3(2):77–101CrossRef Braun V, Clarke V (2006) Using thematic analysis in psychology. Qual Res Psychol 3(2):77–101CrossRef
43.
go back to reference Tong A, Sainsbury P, Craig J (2007) Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care 19(6):349–357PubMedCrossRef Tong A, Sainsbury P, Craig J (2007) Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care 19(6):349–357PubMedCrossRef
44.
go back to reference Menko FH et al (2019) The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice. Fam Cancer 18:127–135PubMedCrossRef Menko FH et al (2019) The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice. Fam Cancer 18:127–135PubMedCrossRef
46.
go back to reference Piovesana A, Senior G (2018) How small is big: sample size and skewness. Assessment 25(6):793–800PubMedCrossRef Piovesana A, Senior G (2018) How small is big: sample size and skewness. Assessment 25(6):793–800PubMedCrossRef
47.
go back to reference Bradbury AR et al (2016) Patient feedback and early outcome data with a novel tiered-binned model for multiplex breast cancer susceptibility testing. Genet Med 18(1):25–33PubMedCrossRef Bradbury AR et al (2016) Patient feedback and early outcome data with a novel tiered-binned model for multiplex breast cancer susceptibility testing. Genet Med 18(1):25–33PubMedCrossRef
48.
go back to reference Kroneman M et al (2016) Netherlands: health system review. Health Syst Transit 18(2):1–240PubMed Kroneman M et al (2016) Netherlands: health system review. Health Syst Transit 18(2):1–240PubMed
49.
go back to reference Van Der Heide I et al (2013) The relationship between health, education, and health literacy: results from the Dutch adult literacy and life skills survey. J Health Commun 18(sup1):172–184PubMedPubMedCentralCrossRef Van Der Heide I et al (2013) The relationship between health, education, and health literacy: results from the Dutch adult literacy and life skills survey. J Health Commun 18(sup1):172–184PubMedPubMedCentralCrossRef
50.
go back to reference Harrison C et al (2023) Family communication and results disclosure after germline sequencing: a mixed methods study. Patient Educ Couns 114:107800PubMedCrossRef Harrison C et al (2023) Family communication and results disclosure after germline sequencing: a mixed methods study. Patient Educ Couns 114:107800PubMedCrossRef
51.
go back to reference Sanz J et al (2010) Uptake of predictive testing among relatives of BRCA1 and BRCA2 families: a multicenter study in northeastern Spain. Fam Cancer 9:297–304PubMedCrossRef Sanz J et al (2010) Uptake of predictive testing among relatives of BRCA1 and BRCA2 families: a multicenter study in northeastern Spain. Fam Cancer 9:297–304PubMedCrossRef
Metadata
Title
Men with metastatic prostate cancer carrying a pathogenic germline variant in breast cancer genes: disclosure of genetic test results to relatives
Authors
Michiel Vlaming
Margreet G. E. M. Ausems
Gina Schijven
Inge M. van Oort
C. Marleen Kets
Fenne L. Komdeur
Lizet E. van der Kolk
Rogier A. Oldenburg
Rolf H. Sijmons
Lambertus A. L. M. Kiemeney
Eveline M. A. Bleiker
Publication date
09-05-2024
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 2/2024
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-024-00377-0

Other articles of this Issue 2/2024

Familial Cancer 2/2024 Go to the issue